| Popis: |
Cancer chemotherapies, despite recent advances, are still limited because of their toxic effects and lack of efficacy on the nonproliferating fraction of malignant cells. The use of agents which could target specifically malignant cells might improve the selectivity of systemic chemotherapy. As an illustration of the promise of this concept, some monoclonal antibodies (MoAb) directed against a tumor-associated antigen have been used in vivo to treat cancer patients, including non-B, non-T acute lymphoblastic leukemias (CALL) [1], T-ALL [2], B and T cell lymphomas [3–7], chronic lymphocytic leukemias (CLL) [8–10], or solid tumors [11–13]. |
